|
Andany MA, Kasiske BL. Dyslipidemia and its management
after renal transplantation. J Nephrol. 2001;14 (suppl 4):S81-S88. Bachelder VD, Muehlstedt SG, Smith CL.
Hyperphosphatemia in a burn patient. J Burn Care Rehabil. 2001;22(2):187-189. Balogun RA, Sahadevan M, Sevigny J, Kaplan AA.
Impact of therapeutic plasma exchange on cyclosporine kinetics during
membrane-based lipid apheresis. Am J Kidney Dis. 2001;37:1286-1289 Brenner BM, Cooper ME, de Zeeuw D, Keane WF,
et al. Effects of losartan on renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin
RB, O'Donnell MP, Rabb H. Identification of the CD4(+) T cell as
a major pathogenic factor in ischemic acute renal failure. J Clin Invest.
2001;108(9):1283-1290. Burne MJ, Elghandour A, Haq M, Saba SR, Norman J, Condon
T, Bennett F, Rabb H. IL-1 and TNF independent pathways mediate
ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury. J Leukoc Biol.
2001;70(2):192-198. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular
disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38(4
suppl. 1):S26-S29. (Also listed under Cardiology) Collins AJ, Li S, St Peter W, et al. Death,
hospitalization, and economic associations among incident hemodialysis
patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12(11):2465-2473. Eknoyan G, Levey AS, Levin NW, Keane WF. The
national epidemic of chronic kidney disease: What we know and what we
can do. Postgrad Med. 2001;110(3):23-29. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid
reduction on the progression of renal disease: a meta-analysis. Kidney
Int. 2001;59(1):260-269. Hebert LA, Spetie DN, Keane WF. The urgent call
of albuminuria/proteinuria. Heeding its significance in early detection
of kidney disease. Postgrad Med. 2001;110(4):79-82,87-88,93-96. Hernandez D, Hanson E, Kasiske MK, Danielson B, Roel
J, Kasiske BL. Cytomegalovirus disease is not a major risk factor
for ischemic heart disease after renal transplantation. Transplantation.
2001;72(8):1395-1399. (Also listed under Clinical Epidemiology) Hotchkiss JR, Rabb H. Acute renal failure. In:
Dries DJ, ed. 5th Critical Care Refresher Course. Anaheim, CA: Society
of Critical Care Medicine. 2001:177-192. Kasiske BL, Andany MA, Hernandez D, Silkensen
J, Rabb H, McClean J, Roel JP, Danielson B. Comparing methods
for monitoring serum creatinine to predict late renal allograft failure.
Am J Kidney Dis. 2001;38(5):1065-1073. (Also listed under Clinical Epidemiology) Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger
B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute
renal allograft rejection. Transplantation. 2001;72(2):223-227. Kasiske BL, Snyder J, Matas A, Collins A
(for the USRDS). The impact of transplantation on survival with kidney
failure (Chapter 11). In: Cecka JM, Terasaki PI, eds. Clinical Transplantations
2000. Los Angeles, CA: UCLA Immunogenetics Center; 2001:135-143. Kasiske BL. Epidemiology of cardiovascular disease
after renal transplantation. Transplantation. 2001;72(6 suppl.):S5-S8. Kasiske BL. The evaluation of prospective renal
transplant recipients. In: Greenberg A, ed. Primer on Kidney Diseases.
New York, NY: Academic Press; 2001:455-459. Kasiske BL. The kidney in cardiovascular disease.
Ann Intern Med. 2001;134(8):707-709. Keane WF, Brenner BM, Mazzu A, Agro A. The CHORUS
(cerivastatin in heart outcomes in renal disease: understanding survival)
protocol: a double-blind, placebo-controlled trial in patients with ESRD.
Am J Kidney Dis. 2001;37(1 suppl. 2):S48-S53. Keane WF. Advances in nutrition and metabolism
in renal disease: introduction. Am J Kidney Dis. 2001;37(1 suppl. 2):S1. Keane WF. Metabolic pathogenesis of cardiorenal
disease. Am J Kidney Dis. 2001;38(6):1372-1375. Keshaviah P, Collins AJ, Ma JZ, Churchill DN,
Thorpe KE. Survival comparison between hemodialysis and peritoneal dialysis
based on matched doses of delivered therapy. J Am Soc Nephrol. 2001;13(suppl.
1):S48-S52. Massy ZA, Swan SK. Cyclooxygenase-2 and atherosclerosis:
friend or foe? Nephrol Dial Transplant. 2001;16(12):2286-2289. Modi KS, Rao VK. Atheroembolic renal disease.
J Am Soc Nephrol. 2001;12(18):1781-1787. Nemoto T, Burne MJ, Daniels F, O'Donnell MP, Crosson
J, Berens K, Issekutz A, Kasiske BL, Keane WF, Rabb H. Small molecule
selectin ligand inhibition improves outcome in ischemic acute renal failure.
Kidney Int. 2001;60(6):2205-2214. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant
erythropoietin rapidly treats anemia in ischemic acute renal failure.
Kidney Int. 2001;59(1):246-251. Nissenson AR, Collins AJ, Dickmeyer J, et al.
Evaluation of disease-state management of dialysis patients. Am J Kidney
Dis. 2001;37(5):938-944. Nissenson AR, Collins AJ, Hurley J, Petersen
H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients
with chronic renal insufficiency: current practice patterns. J Am Soc
Nephrol. 2001;12(8):1713-1720. Nissenson AR, Pereira BJ, Collins AJ, Steinberg
EP. Prevalence and characteristics of individuals with chronic kidney
disease in a large health maintenance organization. Am J Kidney Dis. 2001;37(6):1177-1183. Norden MA, Rabb H. Two haemodialysis patients
with unclear abdominal symptoms of similar origin. Nephrol Dial Transplant.
2001;16(12):2426-2428. (Also listed under Internal Medicine Residency
Program) O'Donnell MP. Mechanisms and clinical importance
of hypertriglyceridemia in the nephrotic syndrome. Kidney Int. 2001;59(1):380-382. Obrador GT, Roberts T, St Peter WL, Frazier E,
Pereira BJ, Collins AJ. Trends in anemia at initiation of dialysis
in the United States. Kidney Int. 2001;60(5):1875-1884. Parving HH, Brenner BM, Copper ME, de Zeeuw D, Keane
WF, et al. Effect of losartan on renal and cardiovascular complications
of patients with type 2 diabetes and nephropathy [in Danish]. Ugeskr Laeger.
2001;163(40):5514-5519. Rabb H, Chamoun F, Hotchkiss J. Molecular mechanisms
underlying combined kidney-lung dysfunction during acute renal failure.
Contrib Nephrol. 2001;132:41-52. (Also listed under Internal Medicine
Residency Program) Rabb H, Modi K, O'Donnell M. Leukocytes
and leukocyte adhesion molecules as mediators of glomerular, tubular and
vascular injury to the kidney. In: Massry S, Glassock RJ, eds. Textbook
of Nephrology, 4th ed. Phildealphia, PA: Lippincott Williams & Wilkins;
2001. Rabb H, Star R. Inflammatory mediators of renal
ischemic reperfusion injury. In: Molitoris W, Finn W, eds. Acute Renal
Failure. A Companion to Brenner BM, ed. The Kidney. Philadelphia, PA:
Harcourt Health Sciences; 2001. Silkensen JR, Kasiske BL. Immunosuppression withdrawal.
Curr Opin Organ Transplant. 2001;6(2):169-174. Smith CL, Kristensen C, Davis M, Abraham PA.
An evaluation of the physicochemical risk for renal stone disease during
pregnancy. Clin Nephrol. 2001;55(3):205-211. Weinstock Brown W, Keane WF. Proteinuria and
cardiovascular disease. Am J Kidney Dis. 2001;38(4 suppl 1):S8-S13. Whitwam W, Lewis M, Rabb H. Alopecia in three
women of Southeast Asian descent with chronic renal failure: possible
association with erythropoietin use. Am J Kidney Dis. 2001;37(1):E9. (Also
listed under Internal Medicine Residency Program) Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast
of the number of patients with end-stage renal disease in the United States
to the year 2010. J Am Soc Nephrol. 2001;12(12):2753-2758. |
